

Table 1. Baseline characteristics of patients stratified by phase angle in tertiles.

	All	T1	T2	T3	P value
No. of patients	1,078	360	359	359	
Age, mean $\pm$ SD, years	58.9 $\pm$ 9.1	63.0 $\pm$ 9.3	58.5 $\pm$ 7.8	55.1 $\pm$ 8.5	<0.001
Male, no. (%)	550 (51.0)	109 (30.3)	178 (49.6)	263 (73.3)	<0.001
Ethnicity, no. (%)					0.646
Chinese	571 (53.0)	193 (53.6)	197 (54.9)	181 (50.4)	
Malay	199 (18.5)	70 (19.4)	64 (17.8)	65 (18.1)	
Indian	268 (24.9)	85 (23.6)	88 (24.5)	95 (26.5)	
Others	40 (3.7)	12 (3.3)	10 (2.8)	18 (5.0)	
DM duration, mean $\pm$ SD, years	12.1 $\pm$ 9.4	14.6 $\pm$ 10.6	12.1 $\pm$ 9.1	9.5 $\pm$ 7.7	<0.001
BMI, mean $\pm$ SD, kg/m <sup>2</sup>	27.5 $\pm$ 4.9	27.0 $\pm$ 5.1	27.4 $\pm$ 4.7	28.1 $\pm$ 4.9	0.015
SBP, mean $\pm$ SD, mmHg	139.1 $\pm$ 17.7	144.4 $\pm$ 19.1	137.6 $\pm$ 16.9	135.2 $\pm$ 15.5	<0.001
HbA1c, mean $\pm$ SD, %	7.8 $\pm$ 1.3	7.8 $\pm$ 1.3	7.9 $\pm$ 1.2	7.7 $\pm$ 1.2	0.096
LDL-C, mean $\pm$ SD, mmol/L	2.7 $\pm$ 0.8	2.7 $\pm$ 0.9	2.7 $\pm$ 0.7	2.8 $\pm$ 0.8	0.374
TG, median (IQR), mmol/L	1.4 (1.0–1.9)	1.3 (1.0–1.9)	1.4 (1.0–1.9)	1.4 (1.1–2.0)	0.568
eGFR, mean $\pm$ SD, mL/min/1.73m <sup>2</sup>	85.1 $\pm$ 24.7	80.9 $\pm$ 26.6	87.3 $\pm$ 24.1	87.1 $\pm$ 22.6	<0.001
Rate of eGFR change, median (IQR), mL/min/1.73m <sup>2</sup> /year	-1.3 (-3.6 to 0.0)	-1.5 (-4.0 to -0.1)	-1.3 (-3.4 to 0.0)	-1.0 (-3.2 to 0.1)	0.051
Baseline eGFR category, no. (%)					0.005
G1, $\geq$ 90mL/min/1.73m <sup>2</sup>	568 (52.7)	163 (45.3)	206 (57.4)	199 (55.4)	
G2, 60–89mL/min/1.73m <sup>2</sup>	320 (29.7)	110 (30.6)	97 (27.0)	113 (31.5)	
G3a, 45–59mL/min/1.73m <sup>2</sup>	90 (8.4)	39 (10.8)	29 (8.1)	22 (6.1)	
G3b, 30–44mL/min/1.73m <sup>2</sup>	62 (5.8)	29 (8.1)	18 (5.0)	15 (4.2)	
G4, 15–29mL/min/1.73m <sup>2</sup>	38 (3.5)	19 (5.3)	9 (2.5)	10 (2.8)	
Last follow-up eGFR category, no. (%)					<0.001
G1, $\geq$ 90mL/min/1.73m <sup>2</sup>	358 (33.2)	85 (23.6)	128 (35.7)	145 (40.4)	
G2, 60–89mL/min/1.73m <sup>2</sup>	339 (31.5)	109 (30.3)	106 (29.5)	124 (34.5)	
G3a, 45–59mL/min/1.73m <sup>2</sup>	140 (13.0)	48 (13.3)	52 (14.5)	40 (11.1)	
G3b, 30–44mL/min/1.73m <sup>2</sup>	92 (8.5)	42 (11.7)	33 (9.2)	17 (4.7)	
G4, 15–29mL/min/1.73m <sup>2</sup>	77 (7.1)	40 (11.1)	21 (5.9)	16 (4.5)	
G5, <15mL/min/1.73m <sup>2</sup>	72 (6.7)	36 (10.0)	19 (5.3)	17 (4.7)	
uACR, median (IQR), mg/g	21.7 (7.3–84.5)	35.0 (10.0–156.4)	20.0 (7.0–88.3)	17.3 (5.3–53.0)	<0.001
Use of insulin, no. (%)	312 (29.0)	111 (30.8)	119 (33.4)	82 (22.8)	0.005
Use of RAS antagonist, no. (%)	673 (62.5)	248 (68.9)	214 (59.8)	211 (58.8)	0.009
Phase angle, mean $\pm$ SD, °	5.5 $\pm$ 0.9	4.5 $\pm$ 0.4	5.4 $\pm$ 0.2	6.5 $\pm$ 0.7	<0.001

BMI: body mass index; DM: diabetes mellitus; eGFR: estimated glomerular filtration rate; HbA1c: haemoglobin A1c; IQR: interquartile range; LDL-C: low-density lipoprotein cholesterol; RAS: renin-angiotensin system; SBP: systolic blood pressure; SD: standard deviation; TG: triglycerides; uACR: urinary albumin-to-creatinine ratio